Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE) : a double-blind, randomised, phase 2 trial

Hussain, S.A. orcid.org/0000-0003-1552-511X, Lester, J.F., Jackson, R. et al. (17 more authors) (2022) Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE) : a double-blind, randomised, phase 2 trial. The Lancet Oncology, 23 (5). pp. 650-658. ISSN 1470-2045

Abstract

Metadata

Authors/Creators:
  • Hussain, S.A. ORCID logo https://orcid.org/0000-0003-1552-511X
  • Lester, J.F.
  • Jackson, R.
  • Gornall, M.
  • Qureshi, M.
  • Elliott, A.
  • Crabb, S.J.
  • Huddart, R.A.
  • Vasudev, N.
  • Birtle, A.J.
  • Worlding, J.
  • James, N.D.
  • Parikh, O.
  • Vilarino-Varela, M.
  • Alonzi, R.
  • Linch, M.D.
  • Riaz, I.B.
  • Catto, J.W.F.
  • Powles, T.
  • Jones, R.J.
Copyright, Publisher and Additional Information: © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Keywords: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Double-Blind Method; Female; Humans; Indoles; Male; Muscles; Neoadjuvant Therapy; Urinary Bladder Neoplasms
Dates:
  • Published (online): 11 April 2022
  • Published: May 2022
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield)
Funding Information:
FunderGrant number
Boehringer Ingelheimn/a
Depositing User: Symplectic Sheffield
Date Deposited: 10 May 2022 14:09
Last Modified: 11 May 2022 09:40
Status: Published
Publisher: Elsevier BV
Refereed: Yes
Identification Number: https://doi.org/10.1016/s1470-2045(22)00158-9
Related URLs:

Share / Export

Statistics